Cboe UK CHF

Novartis AG (NOVNZ.XC)

Compare
87.03 -1.12 (-1.27%)
At close: 4:19:58 PM GMT
Loading Chart for NOVNZ.XC
DELL
  • Previous Close 88.15
  • Open 87.43
  • Bid 86.98 x --
  • Ask 87.03 x --
  • Day's Range 86.85 - 88.12
  • 52 Week Range 83.65 - 102.72
  • Volume 607,351
  • Avg. Volume 507,555
  • Market Cap (intraday) 175.122B
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 17.03
  • EPS (TTM) 5.11
  • Earnings Date Jan 31, 2025
  • Forward Dividend & Yield 3.30 (3.74%)
  • Ex-Dividend Date Mar 7, 2024
  • 1y Target Est --

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

www.novartis.com

76,057

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NOVNZ.XC

View More

Performance Overview: NOVNZ.XC

Trailing total returns as of 12/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NOVNZ.XC
6.69%
MSCI WORLD
17.19%

1-Year Return

NOVNZ.XC
5.79%
MSCI WORLD
18.61%

3-Year Return

NOVNZ.XC
8.56%
MSCI WORLD
18.29%

5-Year Return

NOVNZ.XC
8.56%
MSCI WORLD
59.17%

Compare To: NOVNZ.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NOVNZ.XC

View More

Valuation Measures

Annual
As of 12/18/2024
  • Market Cap

    176.02B

  • Enterprise Value

    192.21B

  • Trailing P/E

    17.24

  • Forward P/E

    12.05

  • PEG Ratio (5yr expected)

    2.94

  • Price/Sales (ttm)

    4.06

  • Price/Book (mrq)

    4.56

  • Enterprise Value/Revenue

    4.31

  • Enterprise Value/EBITDA

    10.93

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    35.25%

  • Return on Assets (ttm)

    10.59%

  • Return on Equity (ttm)

    28.79%

  • Revenue (ttm)

    49.94B

  • Net Income Avi to Common (ttm)

    11.76B

  • Diluted EPS (ttm)

    5.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.85B

  • Total Debt/Equity (mrq)

    74.03%

  • Levered Free Cash Flow (ttm)

    5.68B

Research Analysis: NOVNZ.XC

View More

Company Insights: NOVNZ.XC

Research Reports: NOVNZ.XC

View More

People Also Watch